Clinical heterogeneity in Fabry disease
Fabry disease is an X-linked, lysosomal storage disease (OMIM: 301500), caused by α-galactosidase A deficiency, resulting in accumulation of its substrates, glycosphingolipids, primarily – globotriaosylceramide, in the lysosomes of multiple cell types with multi-system clinical manifestations, even...
Saved in:
| Main Author: | G. N. Salogub |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-12-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern Approach to Fabry Disease Diagnosis and Management in Children
by: Olga Ya. Smirnova, et al.
Published: (2024-02-01) -
Current treatment status of fabry disease in South Korea: a longitudinal National health insurance service data-based study
by: DoHyeon Lee, et al.
Published: (2025-07-01) -
Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease
by: V. I. Ignatyeva, et al.
Published: (2019-01-01) -
Impaired plasma membrane calcium ATPase activity and mitochondrial dysfunction contribute to calcium dysregulation in Fabry disease-related painful neuropathy
by: Francesco Formaggio, et al.
Published: (2025-09-01) -
Current status of the immunogenicity of enzyme replacement therapy in fabry disease
by: Jorge F. Gómez-Cerezo, et al.
Published: (2025-05-01)